TICKERNERD
Menu
HINDHINDHealthcare · Biotechnology

HIND Stock Forecast: Vyome Holdings, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$2.10

The 3 Wall Street analysts covering Vyome Holdings, Inc. hold a median 12-month price target of $8 — +281.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 72 of 100 as at 19 Sept 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$13.8M
Ticker Nerd rank
72 / 100
Median analyst target
$8.00
Analysts covering
3
Revenue$27K−86.4% y/y
Operating income−$863K
Net income−$720K
Free cash flow−$904K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

HIND stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Vyome Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
72 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
99
Size
90
Value
72
Revisions
67
Volatility
53
Growth
52
Quality
52
Issuance
33
Momentum
18

Accruals (99): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (18): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

HIND stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HIND, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $3.50Median $8.00High $15.00

The green dot is the last close — the median target sits +281.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
3 Sept 2026Chardan CapitalInitiatesBuy$3.50
2 Oct 2025Maxim GroupAssumesBuy$15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HIND appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

HIND analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Vyome Holdings, Inc. (HIND) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.4×

Cheaper than 79% of US stocks

Price / sales
106.6×

Cheaper than 4% of US stocks

Price / book
2.3×

Cheaper than 41% of US stocks

EV / EBITDA
−1.7×

Cheaper than 70% of US stocks

Growth & margins
Revenue growth (YoY)
−46.0%

Higher than 6% of US stocks

Earnings growth (YoY)
−86.4%

Higher than 4% of US stocks

Gross margin
43.2%

Higher than 54% of US stocks

Operating margin
−3200.0%

Higher than 4% of US stocks

Net margin
68.4%

Higher than 98% of US stocks

Returns & dividend
Return on equity
−999.2%

Higher than 2% of US stocks

Return on assets
−48.8%

Higher than 8% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Vyome Holdings, Inc. (HIND) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Vyome Holdings, Inc. has a market value of $13.8M and an enterprise value of $7.1M.

  • Revenue in the twelve months to 30 June 2026: $130K. The latest quarter shrank 46.0% year on year.

  • Net income over the same four quarters: −$11.6M, a −8926.8% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$5.6M.

  • Shares outstanding: 7.0M.

  • Trailing P/E: −0.4×; forward P/E: −2.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Vyome Holdings, Inc. employs 9 people — $14K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Sept 2026

Data provided by Twelve Data

Peers

HIND vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
HINDVyome Holdings, Inc.$13.8M
72
NIKINiki Biosolutions, Inc.$14.7M
12
MBRXMoleculin Biotech, Inc.$15.1M
25
DAREDaré Bioscience, Inc.$15.2M
27
PASGPassage Bio, Inc.$15.3M
43
LSTALisata Therapeutics, Inc.$15.3M
56
CNSYCerenome, Inc.$15.4M
17

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Vyome Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest HIND news & analysis

Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer

Business Wire · 14 Sept 2026positive

Vyome Holdings, Inc. announced the appointment of Jerry Leonard, CPA, MBA, as Chief Financial Officer, effective September 1, 2026. Leonard will oversee the company's financial operations, financial reporting, and accounting functions.

Why it matters — HIND watchers would note the appointment of an experienced public company finance executive to oversee the company's financial operations.

FAQ

Frequently asked questions about HIND stock

What is the HIND stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Vyome Holdings, Inc. have a median 12-month price target of $8, with estimates ranging from $3.5 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HIND stock a buy right now?

Of the 3 analysts covering Vyome Holdings, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vyome Holdings, Inc. 72 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HIND?

As at 19 Sept 2026, Vyome Holdings, Inc. ranks 72 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (99 of 100).

Will HIND stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +281.0% from the last close, and Ticker Nerd's factor model ranks Vyome Holdings, Inc. 72 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HIND stock forecast for 2030?

No analyst covering Vyome Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HIND are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3.5 to $15 over the next 12 months.

What does Vyome Holdings, Inc. do?

Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments.

What is the latest news on HIND?

The most recent item we track (Business Wire, 14 Sept 2026): "Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer". Vyome Holdings, Inc. announced the appointment of Jerry Leonard, CPA, MBA, as Chief Financial Officer, effective September 1, 2026. Leonard will oversee the company's financial operations, financial reporting, and accounting functions.

Company

About Vyome Holdings, Inc.

Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.

CEO Mr. Venkateswarlu Nelabhotla M.B.A. · 9 employees · United States · https://www.vyometx.com